The United States market has shown notable resilience, with a 27% increase over the past year and a forecasted annual earnings growth of 17%. For investors looking beyond established giants, penny stocks—often representing smaller or newer companies—can offer intriguing opportunities. Although the term may seem outdated, these stocks remain relevant by providing potential growth when supported by robust financial health.

Let's explore several standout options from the results in the screener.

Telos (TLS)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Telos Corporation, along with its subsidiaries, offers cyber, cloud, and enterprise security solutions both in the United States and internationally, with a market cap of approximately $329.20 million.

Operations: The company's revenue is derived from two main segments: Secure Networks, generating $12.18 million, and Security Solutions, contributing $169.75 million.

Market Cap: $329.2M

Telos Corporation, with a market cap of US$329.20 million, recently reported a revenue increase to US$47.74 million for Q1 2026 and net income of US$2.02 million, marking an improvement from the previous year's loss. Despite being unprofitable overall, Telos has no debt and maintains sufficient cash runway for over three years, supported by positive free cash flow. The company has been actively repurchasing shares under its buyback plan while expanding its TSA PreCheck enrollment services nationwide. However, significant insider selling in recent months might warrant cautious observation for potential investors in penny stocks.

SOPHiA GENETICS (SOPH)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: SOPHiA GENETICS SA is a cloud-native software technology company in the healthcare sector with a market cap of $335.98 million.

Operations: The company generates revenue from its healthcare software segment, amounting to $81.18 million.

Market Cap: $335.98M

SOPHiA GENETICS, with a market cap of US$335.98 million, is navigating the challenges typical of penny stocks in the healthcare sector. Despite being unprofitable and experiencing increased losses over five years, it has a stable cash runway exceeding one year and more cash than debt. Recent strategic alliances, such as with Synnovis for liquid biopsy testing in the UK and Mount Sinai Health System to enhance genomic testing capabilities, highlight its commitment to expanding precision medicine applications. The company forecasts revenue growth of 20% to 22% for 2026 but remains under analyst scrutiny due to its negative return on equity and rising debt levels.

Butterfly Network (BFLY)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Butterfly Network, Inc. develops, manufactures, and commercializes ultrasound imaging solutions globally with a market cap of $1.07 billion.

Operations: The company generates revenue of $102.92 million from offering an AI-enhanced personal ultrasound solution.

Market Cap: $1.07B

Butterfly Network, with a market cap of US$1.07 billion, stands out in the penny stock landscape by leveraging AI-enhanced ultrasound technology to drive revenue growth. Despite being unprofitable and experiencing high share price volatility, it has reduced losses over the past five years and maintains a strong cash position with no debt. Recent FDA clearance for its gestational age tool underscores its innovative edge in healthcare solutions. The company forecasts 20% to 24% revenue growth for 2026, supported by strategic leadership changes including the appointment of Caroll H. Neubauer to its board, enhancing governance expertise.

Make It Happen

• Investigate our full lineup of 351 US Penny Stocks right here.
• Curious About Other Options? Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.